Cuộc họp công bố kết quả kinh doanh Q3 2026 của Alkermes (ALKS): Doanh thu 480,1 triệu USD và các yếu tố thúc đẩy từ Orexin
Doanh thu Quý 3/2026 của Alkermes đạt 480,1 triệu USD khi doanh số các sản phẩm độc quyền tăng 31%. Ban lãnh đạo giữ nguyên định hướng kết quả kinh doanh và nêu chi tiết sáu kết quả thử nghiệm orexin sắp tới.
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.